Literature DB >> 913025

Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.

S M Pond, D J Birkett, D N Wade.   

Abstract

Tolbutamide half-life was increased by chronic administration of sulfaphenazole (9.5 hr to 28.6 hr, n = 2), phenylbutazone (7.9 hr to 23.1 hr, n = 8), and oxyphenbutazone (8.1 hr to 30.2 hr, n = 2). The rate of elimination of tolbutamide was decreased within 1 to 2 hr of a single dose of sulfaphenazole and the tolbutamide half-life was increased from 9.2 hr to 25.7 hr (n = 2). In contrast, phenylbutazone and oxyphenbutazone, administered as single oral doses of 800 mg, had no immediate effect on tolbutamide elimination. At times greater than 20 to 30 hr after the single dose of phenylbutazone or oxyphenbutazone the rate of tolbutamide elimination was decreased. It is suggested that phenylbutazone and oxyphenbutazone act by inducing form of cytochrome P-450 with low activity for tolbutamide hydroxylation, whereas sulfaphenazole acts by direct inhibition of the microsomal mixed function oxidase system.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 913025     DOI: 10.1002/cpt1977225part1573

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  33 in total

1.  Systemic bioavailability of fluticasone proprionate.

Authors:  B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

2.  Applying organ clearance concepts in a clinical setting.

Authors:  Jorge Duconge
Journal:  Am J Pharm Educ       Date:  2008-10-15       Impact factor: 2.047

3.  Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect.

Authors:  D Zhou; Y Lu; M S Steiner; J T Dalton
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  Matching the Drug to the Patient: The rational use of antiarthritic drugs.

Authors:  P Lee
Journal:  Can Fam Physician       Date:  1991-01       Impact factor: 3.275

Review 5.  Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

Review 6.  The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs.

Authors:  R E Ferner; S Chaplin
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

7.  Tolbutamide 4-hydroxylase activity of human liver microsomes: effect of inhibitors.

Authors:  H S Purba; D J Back; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of phenylbutazone.

Authors:  J Aarbakke
Journal:  Clin Pharmacokinet       Date:  1978 Sep-Oct       Impact factor: 6.447

Review 9.  The problems and pitfalls of NSAID therapy in the elderly (Part II).

Authors:  A G Johnson; R O Day
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

10.  Tolbutamide as a model drug for the study of enzyme induction and enzyme inhibition in the rat.

Authors:  D J Back; F Sutcliffe; J F Tjia
Journal:  Br J Pharmacol       Date:  1984-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.